Brazil: Demand for GLP-1 companion products in Brazil is projected to grow at around an 11.8% CAGR through 2036, supported by expanding GLP-1 user base for obesity management and diabetes care, and growing demand for high-quality and convenient companion product formats such as sachets, bars, and liquid shots
de Boer et al., 2019), and clinical applications have been explored for mood symptoms in autism spectrum disorder (Ghaleiha et al., 2013), treatment-resistant schizophrenia (Pillinger et al., 2019), treatment-resistant obsessive-compulsive disorder (Grant et al., 2007), and methamphetamine dependency (Farahzadi et al., 2019) among others
it demands a clinical-grade ecosystem
H.KirknessJ
Accessed April 2026
The review process takes 3 to 14 business days for standard prior authorization, 24 to 72 hours for urgent requests